数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

   KPRX
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

股本结构

单位：万股
公告日期 2026-08-07 2026-08-07 2026-05-08 2026-04-30 2026-05-08 2026-03-25
证券总股本 442.44 442.72 443.19 443.24 399.35 395.06
普通股本 442.44 442.72 443.19 443.24 399.35 395.06
优先股 未披露 0.04 未披露 未披露 0.04 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2026-08-05 2026-06-30 2026-05-06 2026-04-16 2026-03-31 2026-03-21
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2026-08-07 442.44 未披露 定期报告 2026-08-05
2026-08-07 442.72 0.04
更多>>
From March 31,2026 to June 30,2026 Issuance of Common Stock and Warrants from Private Placement, Net of Offering Costs of $72 thousand Shares Withheld for Employee Taxes on Vested Restricted Stock
2026-06-30
2026-05-08 443.19 未披露 定期报告 2026-05-06
2026-04-30 443.24 未披露 定期报告 2026-04-16
2026-05-08 399.35 0.04
更多>>
From December 31,2025 to March 31,2026 Issuance of common stock from restricted stock awards Shares withheld for employee taxes on vested restricted stock Issuance of common stock from warrant exercises
2026-03-31
2026-03-25 395.06 未披露 定期报告 2026-03-21
2026-03-25 376.17 0.04
更多>>
From December 31, 2024 to December 31, 2025 Issuance of Common Stock from Warrant Exercises Issuance of Common Stock from Restricted Stock Awards
2025-12-31
2025-11-07 367.79 未披露 定期报告 2025-11-05
2025-11-07 343.35 未披露 定期报告 2025-09-30
2025-08-08 343.35 0.04
更多>>
From March 31, 2025 to June 30, 2025 Issuance of Common Stock from Warrant Exercises Issuance of Common Stock from Restricted Stock Awards
2025-06-30
2025-04-30 304.39 未披露 定期报告 2025-04-16
2024-11-08 300.08 0.04
更多>>
From June 30, 2024 to September 30, 2024 Adjustments Due to the Rounding Impact from the Reverse Stock Split for Fractional Shares Issuance of Common Stock from Restricted Stock Awards
2024-09-30
2024-08-09 297.05 0.04
更多>>
From March 31, 2024 to June 30, 2024 Adjustments Due to the Rounding Impact from the Reverse Stock Split for Fractional Shares Issuance of Common Stock from Warrant Exercises
2024-06-30
2024-06-07 297.06 未披露
更多>>
1-for-9 reverse stock split of the Company’s common stock
2024-06-11
2024-06-07 2673.51 未披露 定期报告 2024-06-07
2024-05-10 2625.62 0.04
更多>>
From December 31, 2023 to March 31, 2024 Issuance of Common Stock and Warrants from Private Placement, Net of Offering Costs of $1.2 million Issuance of Common Stock from Warrant Exercises
2024-03-31
2024-03-25 2625.62 未披露 定期报告 2024-03-15
2024-03-25 770.56 0.04
更多>>
From December 31, 2022 to December 31, 2023 Issuance of Common Stock from Restricted Stock Awards Conversion of Series F Preferred Stock into Common Stock Issuance of Shares of Common Stock from Warrant Exercises Issuance of Common Stock from ELOC Purchases Issuance of Common Stock from Private Placement, Net of Offering Costs of $84,285 Issuance of Common Stock from Public Offering, Net of Offering Costs of $132,684
2023-12-31
2023-11-09 768.92 0.04
更多>>
From June 30, 2023 to September 30, 2023 Conversion of Series F Preferred Stock into Common Stock Issuance of Common Stock from Restricted Stock Awards
2023-09-30
2023-07-21 724.71 未披露 定期报告 2023-07-18
2023-08-08 691.07 0.10
更多>>
From March 31, 2023 to June 30, 2023 Issuance of Stock from Public Offering, Net of Offering Costs of $729,038 Issuance of Common Stock from ELOC Purchases Conversion of Series F Preferred Stock into Common Stock
2023-06-30
2023-06-02 347.19 未披露
更多>>
Common Stock offered by the company 1,447,628 shares
2023-06-06
2023-06-02 202.43 0.0007 定期报告 2023-06-02
2023-04-28 202.43 未披露 定期报告 2023-04-24
2023-05-09 191.93 0.0007
更多>>
From December 31, 2022 to March 31, 2023 Issuance of Common Stock from Warrant Exercises Issuance of Common Stock from Private Placement, Net of Offering Costs of $84,285 Issuance of Common Stock from ELOC Purchases
2023-03-31
2023-03-23 191.93 未披露 定期报告 2023-03-20
2023-02-13 184.93 未披露 定期报告 2023-02-03
2022-12-22 179.65 0.0007 定期报告 2022-12-20
2022-11-09 114.19 未披露 定期报告 2022-11-08
2022-11-09 107.90 0.0007
更多>>
From June 30, 2022 to September 30, 2022 Issuance of Common Stock from Public Offering, Net of Offering Costs of $505,020 Conversion of Series E Preferred Stock into common stock Adjustments Due to the Rounding Impact from the Reverse Stock Split for Fractional Shares Issuance of Series E Preferred Stock from Public Offering, Net of Offering Costs of $136,401
2022-09-30
2022-09-26 107.91 未披露
更多>>
Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split.
2022-09-27
2022-08-15 3676.31 未披露
更多>>
1.Securities offered by 23,695,697 shares of common stock.1,280 shares of Series E Preferred Stock that are convertible into an aggregate of up to 6,400,000 shares of common stock, subject to certain adjustments. 2.The number of shares of common stock to be outstanding after this offering is based on 13,067,426 shares of common stock outstanding as of July 22, 2022
2022-07-26
2022-08-12 1306.74 0.0007
更多>>
From March 31, 2022 to June 30, 2022 Issuance of Common Stock from Panoptes Holdback Shares
2022-06-30
2022-04-15 1266.40 0.0007
更多>>
From December 31, 2020 to December 31, 2021 Issuance of Common Stock from Warrants, Net Conversion of Series C Preferred Stock into Common Stock Conversion of Series D Preferred Stock into Common Stock Issuance of Common Stock from Private Placement, Net of Offering Costs of $11,142 Issuance of Common Stock from Registered Direct Offering, Net of Offering Costs of $993,666 Shares issued to Bayon Shareholders at Acquisition
2021-12-31
2021-11-15 1265.31 未披露 定期报告 2021-11-10
2021-11-15 1261.93 0.0046
更多>>
From June 30, 2021 to September 30, 2021 Conversion of Series C Preferred Stock into Common Stock Issuance of Common Stock from Registered Direct Offering, Net of Offering Costs of $993,666
2021-09-30
2021-08-12 1261.93 未披露 定期报告 2021-08-11
2021-08-11 795.04 未披露 定期报告 2021-08-09
2021-08-12 709.79 0.41 定期报告 2021-06-30
2021-04-16 709.79 0.41 定期报告 2021-04-15
2021-05-12 709.79 0.41 定期报告 2021-03-31
2021-03-25 709.79 未披露 定期报告 2021-03-23
2021-03-25 555.64 0.41
更多>>
From December 31, 2019 to December 31, 2020 Issuance of Common Stock in Offerings, Net of Offering Costs of $498,687 Issuance of Shares of Common Stock from Warrant Exercises Shares Issued to Panoptes Stockholders at Acquisition Issuance of Common Stock from Restricted Stock Award Grants
2020-12-31
2020-05-06 462.68 0.41
更多>>
from December 31, 2018 to March 31, 2020 Issuance of Common Stock in Offerings, Net of Offering Costs of $498,687 Issuance of Common Stock from Restricted Stock Award Grants
2020-03-31
2020-03-04 462.68 未披露 定期报告 2020-03-02
2020-01-03 454.85 未披露 定期报告 2020-01-03
2020-03-04 407.78 0.41
更多>>
from December 31, 2018 to December 31, 2019 Issuance of Common Stock in Offerings, Net of Offering Costs of $97,082 Issuance of Shares of Common Stock from Warrant Exercises Cancellation of Fractional Shares due to Reverse Stock Split Settlement of Fractional Shares due to Reverse Stock Split Cancellation of Restricted Stock
2019-12-31
2019-10-18 363.65 0.41 定期报告 2019-10-18
2019-11-07 303.65 0.41
更多>>
from June 30, 2019 to September 30, 2019 Cancellation of Fractional Shares due to Reverse Stock Split Settlement of Fractional Shares due to Reverse Stock Split Cancellation of Restricted Stock
2019-09-30
2019-08-29 304.50 未披露
更多>>
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced a reverse stock split of its shares of common stock at a ratio of 1-for-15. Upon the commencement of trading on August 30, 2019, the Company's common stock will begin trading on a post-split basis.
2019-08-30
2019-08-08 4567.57 0.41
更多>>
from December 31, 2018 to June 30, 2019 Cancellation and Correction of Restricted Stock Par Value Issuance of Shares of Common Stock from Warrant Exercises
2019-06-30
2019-04-30 4379.07 未披露 定期报告 2019-04-19
2019-05-08 4557.57 0.41
更多>>
from December 31, 2018 to March 31, 2019 Cancellation and Correction of Restricted Stock Par Value
2019-03-31
2019-03-01 4379.07 未披露 定期报告 2019-02-27
2019-03-01 4379.39 0.41
更多>>
from January 1, 2018 to December 31, 2018 Issuance of Common Stock in Offerings, Net of Offering Costs of $1,141,238 Conversion of Series B Preferred Stock Conversion of Series C Preferred Stock into Common Stock Issuance of Common Stock in Offerings, Net of Offering Costs of $1,141,238 Conversion of Series B Preferred Stock into Common Stock Conversion of Series C Preferred Stock into Common Stock Issuance of Common Shares from Warrant Exercises Cancellation of Restricted Stock
2018-12-31
2018-11-13 4344.39 未披露 定期报告 2018-11-09
2018-11-13 4344.41 0.41
更多>>
From January 1, 2018 to September 30, 2018 Conversion of Series B Preferred Stock into Common Stock Issuance of Stock in Offering, Net of Offering Costs of $1,141,238 Conversion of Series C Preferred Stock into Common Stock Issuance of Common Shares from Warrant Exercises
2018-09-30
2018-08-03 4343.91 未披露 定期报告 2018-08-01
2018-08-03 4238.29 0.41
更多>>
From January 1, 2018 to June 30, 2018 Conversion of Series B Preferred Stock into Common Stock Issuance of Stock in Offering, Net of Offering Costs of $1,141,238 Conversion of Series C Preferred Stock into Common Stock Issuance of Common Shares from Warrant Exercises
2018-06-30
2018-05-29 4188.50 未披露 定期报告 2018-05-16
2018-05-29 4173.50 未披露 定期报告 2018-05-14
2018-05-11 4163.50 未披露 定期报告 2018-05-09
2018-05-11 1725.73 0.06 定期报告 2018-03-31
2018-03-02 1725.73 0.06
更多>>
from December 31, 2016 to December 31, 2017 Issuance of Series B Preferred Stock, Net of Offering Costs of $246,333 Conversion of Series B Preferred Stock Issuance of Common Stock in Offerings, Net of Offering Costs of $1,086,736 Exercise of Common Stock Options Issuance of Restricted Stock, Net of Cancellations Issuance of Common Stock from Employee Stock Purchase Plan
2017-12-31
2017-08-04 1720.48 0.06
更多>>
from December 31, 2016 to June 30, 2017 Issuance of Series B Preferred Stock, Net of Offering Costs of $246,333 Conversion of Series B Preferred Stock Issuance of Common Stock in Offerings, Net of Offering Costs of $1,086,736 Exercise of Common Stock Options Issuance of Restricted Stock
2017-06-30
2017-06-05 1093.81 未披露 定期报告 2017-06-02
2017-05-05 1087.81 未披露
更多>>
from December 31, 2016 to March 31, 2017 Issuance of Common Stock in Offering, Net of Offering Costs Exercise of Common Stock Options Issuance of Restricted Stock
2017-03-31
2017-02-23 1023.49 未披露 定期报告 2017-02-17
2017-02-23 1013.09 未披露
更多>>
From December 31,2015 to December 31,2016 Issuance of Series A Preferred Stock Net of Offering Costs Conversion of Series A Preferred Stock Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition Issuance of Holdback Shares from the Jade Acquisition Issuance of Common Stock in Offering, Net of Offering Costs Exercise of Common Stock Options
2016-12-31
2016-11-01 958.59 0.12
更多>>
From December 31, 2015 to September 30, 2016 Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition Issuance of Holdback Shares from the Jade Acquisition Issuance of Common Stock in Offering, Net of Offering Costs Issuance of Series A Preferred Stock, Net of Offering Costs Conversion of Series A Preferred Stock Exercise of Common Stock Options
2016-09-30
2016-08-31 937.59 未披露 定期报告 2016-08-31
2016-08-10 895.19 未披露
更多>>
from December 31, 2015 to June 30, 2016 Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition Issuance of Holdback Shares from the Jade Acquisition Issuance of Common Stock in Offering, Net of Offering Costs Issuance of Series A Preferred Stock, Net of Offering Costs Conversion of Series A Preferred Stock Exercise of Common Stock Options
2016-06-30
2016-05-13 834.64 未披露
更多>>
from December 31, 2015 to March 28, 2016 Shares issued and issuable to Jade Therapeutics, Inc. stockholders at acquisition
2016-03-28
2016-03-30 765.73 未披露
更多>>
from December 31, 2014 to December 31, 2015 Issuance of common stock upon IPO Issuance of common stock in secondary public offering Conversion of preferred stock to common stock at $6.00 per share ($0.01 par value), net of deemed dividend of $8,222,008 Conversion of promissory notes to common stock at $4.20 per share Exercise of common stock options Exercise of common warrants upon initial public offering Issuance of restricted stock Adjustment for fractional shares
2015-12-31
2015-08-12 765.36 未披露 定期报告 2015-08-12
2015-07-31 758.08 未披露 定期报告 2015-07-31
2015-07-28 640.44 未披露 定期报告 2015-07-10
2015-02-04 564.54 未披露 定期报告 2015-02-02
2014-11-20 20.18 3346.57
更多>>
From December 31, 2013 to September 30, 2014 Issuance of shares as settlement of a liability Exercise of common stock options On September 25, 2014, the Company’s Board of Directors approved a 1-for-10.98 reverse split of the Company’s outstanding common stock.
2014-09-30
2014-11-20 18.45 3346.57
更多>>
On September 25, 2014, the Company’s Board of Directors approved a 1-for-10.98 reverse split of the Company’s outstanding common stock.
2014-09-26
2014-07-30 202.55 3840.23 定期报告 2014-07-01
2014-07-30 202.55 3346.57 定期报告 2014-03-31
From March 31,2026 to June 30,2026 Issuance of Common Stock and Warrants from Private Placement, Net of Offering Costs of $72 thousand Shares Withheld for Employee Taxes on Vested Restricted Stock
From December 31,2025 to March 31,2026 Issuance of common stock from restricted stock awards Shares withheld for employee taxes on vested restricted stock Issuance of common stock from warrant exercises
From December 31, 2024 to December 31, 2025 Issuance of Common Stock from Warrant Exercises Issuance of Common Stock from Restricted Stock Awards
From March 31, 2025 to June 30, 2025 Issuance of Common Stock from Warrant Exercises Issuance of Common Stock from Restricted Stock Awards
From June 30, 2024 to September 30, 2024 Adjustments Due to the Rounding Impact from the Reverse Stock Split for Fractional Shares Issuance of Common Stock from Restricted Stock Awards
From March 31, 2024 to June 30, 2024 Adjustments Due to the Rounding Impact from the Reverse Stock Split for Fractional Shares Issuance of Common Stock from Warrant Exercises
1-for-9 reverse stock split of the Company’s common stock
From December 31, 2023 to March 31, 2024 Issuance of Common Stock and Warrants from Private Placement, Net of Offering Costs of $1.2 million Issuance of Common Stock from Warrant Exercises
From December 31, 2022 to December 31, 2023 Issuance of Common Stock from Restricted Stock Awards Conversion of Series F Preferred Stock into Common Stock Issuance of Shares of Common Stock from Warrant Exercises Issuance of Common Stock from ELOC Purchases Issuance of Common Stock from Private Placement, Net of Offering Costs of $84,285 Issuance of Common Stock from Public Offering, Net of Offering Costs of $132,684
From June 30, 2023 to September 30, 2023 Conversion of Series F Preferred Stock into Common Stock Issuance of Common Stock from Restricted Stock Awards
From March 31, 2023 to June 30, 2023 Issuance of Stock from Public Offering, Net of Offering Costs of $729,038 Issuance of Common Stock from ELOC Purchases Conversion of Series F Preferred Stock into Common Stock
Common Stock offered by the company 1,447,628 shares
From December 31, 2022 to March 31, 2023 Issuance of Common Stock from Warrant Exercises Issuance of Common Stock from Private Placement, Net of Offering Costs of $84,285 Issuance of Common Stock from ELOC Purchases
From June 30, 2022 to September 30, 2022 Issuance of Common Stock from Public Offering, Net of Offering Costs of $505,020 Conversion of Series E Preferred Stock into common stock Adjustments Due to the Rounding Impact from the Reverse Stock Split for Fractional Shares Issuance of Series E Preferred Stock from Public Offering, Net of Offering Costs of $136,401
Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split.
1.Securities offered by 23,695,697 shares of common stock.1,280 shares of Series E Preferred Stock that are convertible into an aggregate of up to 6,400,000 shares of common stock, subject to certain adjustments. 2.The number of shares of common stock to be outstanding after this offering is based on 13,067,426 shares of common stock outstanding as of July 22, 2022
From March 31, 2022 to June 30, 2022 Issuance of Common Stock from Panoptes Holdback Shares
From December 31, 2020 to December 31, 2021 Issuance of Common Stock from Warrants, Net Conversion of Series C Preferred Stock into Common Stock Conversion of Series D Preferred Stock into Common Stock Issuance of Common Stock from Private Placement, Net of Offering Costs of $11,142 Issuance of Common Stock from Registered Direct Offering, Net of Offering Costs of $993,666 Shares issued to Bayon Shareholders at Acquisition
From June 30, 2021 to September 30, 2021 Conversion of Series C Preferred Stock into Common Stock Issuance of Common Stock from Registered Direct Offering, Net of Offering Costs of $993,666
From December 31, 2019 to December 31, 2020 Issuance of Common Stock in Offerings, Net of Offering Costs of $498,687 Issuance of Shares of Common Stock from Warrant Exercises Shares Issued to Panoptes Stockholders at Acquisition Issuance of Common Stock from Restricted Stock Award Grants
from December 31, 2018 to March 31, 2020 Issuance of Common Stock in Offerings, Net of Offering Costs of $498,687 Issuance of Common Stock from Restricted Stock Award Grants
from December 31, 2018 to December 31, 2019 Issuance of Common Stock in Offerings, Net of Offering Costs of $97,082 Issuance of Shares of Common Stock from Warrant Exercises Cancellation of Fractional Shares due to Reverse Stock Split Settlement of Fractional Shares due to Reverse Stock Split Cancellation of Restricted Stock
from June 30, 2019 to September 30, 2019 Cancellation of Fractional Shares due to Reverse Stock Split Settlement of Fractional Shares due to Reverse Stock Split Cancellation of Restricted Stock
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced a reverse stock split of its shares of common stock at a ratio of 1-for-15. Upon the commencement of trading on August 30, 2019, the Company's common stock will begin trading on a post-split basis.
from December 31, 2018 to June 30, 2019 Cancellation and Correction of Restricted Stock Par Value Issuance of Shares of Common Stock from Warrant Exercises
from December 31, 2018 to March 31, 2019 Cancellation and Correction of Restricted Stock Par Value
from January 1, 2018 to December 31, 2018 Issuance of Common Stock in Offerings, Net of Offering Costs of $1,141,238 Conversion of Series B Preferred Stock Conversion of Series C Preferred Stock into Common Stock Issuance of Common Stock in Offerings, Net of Offering Costs of $1,141,238 Conversion of Series B Preferred Stock into Common Stock Conversion of Series C Preferred Stock into Common Stock Issuance of Common Shares from Warrant Exercises Cancellation of Restricted Stock
From January 1, 2018 to September 30, 2018 Conversion of Series B Preferred Stock into Common Stock Issuance of Stock in Offering, Net of Offering Costs of $1,141,238 Conversion of Series C Preferred Stock into Common Stock Issuance of Common Shares from Warrant Exercises
From January 1, 2018 to June 30, 2018 Conversion of Series B Preferred Stock into Common Stock Issuance of Stock in Offering, Net of Offering Costs of $1,141,238 Conversion of Series C Preferred Stock into Common Stock Issuance of Common Shares from Warrant Exercises
from December 31, 2016 to December 31, 2017 Issuance of Series B Preferred Stock, Net of Offering Costs of $246,333 Conversion of Series B Preferred Stock Issuance of Common Stock in Offerings, Net of Offering Costs of $1,086,736 Exercise of Common Stock Options Issuance of Restricted Stock, Net of Cancellations Issuance of Common Stock from Employee Stock Purchase Plan
from December 31, 2016 to June 30, 2017 Issuance of Series B Preferred Stock, Net of Offering Costs of $246,333 Conversion of Series B Preferred Stock Issuance of Common Stock in Offerings, Net of Offering Costs of $1,086,736 Exercise of Common Stock Options Issuance of Restricted Stock
from December 31, 2016 to March 31, 2017 Issuance of Common Stock in Offering, Net of Offering Costs Exercise of Common Stock Options Issuance of Restricted Stock
From December 31,2015 to December 31,2016 Issuance of Series A Preferred Stock Net of Offering Costs Conversion of Series A Preferred Stock Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition Issuance of Holdback Shares from the Jade Acquisition Issuance of Common Stock in Offering, Net of Offering Costs Exercise of Common Stock Options
From December 31, 2015 to September 30, 2016 Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition Issuance of Holdback Shares from the Jade Acquisition Issuance of Common Stock in Offering, Net of Offering Costs Issuance of Series A Preferred Stock, Net of Offering Costs Conversion of Series A Preferred Stock Exercise of Common Stock Options
from December 31, 2015 to June 30, 2016 Shares Issued to Jade Therapeutics, Inc. Stockholders at Acquisition Issuance of Holdback Shares from the Jade Acquisition Issuance of Common Stock in Offering, Net of Offering Costs Issuance of Series A Preferred Stock, Net of Offering Costs Conversion of Series A Preferred Stock Exercise of Common Stock Options
from December 31, 2015 to March 28, 2016 Shares issued and issuable to Jade Therapeutics, Inc. stockholders at acquisition
from December 31, 2014 to December 31, 2015 Issuance of common stock upon IPO Issuance of common stock in secondary public offering Conversion of preferred stock to common stock at $6.00 per share ($0.01 par value), net of deemed dividend of $8,222,008 Conversion of promissory notes to common stock at $4.20 per share Exercise of common stock options Exercise of common warrants upon initial public offering Issuance of restricted stock Adjustment for fractional shares
From December 31, 2013 to September 30, 2014 Issuance of shares as settlement of a liability Exercise of common stock options On September 25, 2014, the Company’s Board of Directors approved a 1-for-10.98 reverse split of the Company’s outstanding common stock.
On September 25, 2014, the Company’s Board of Directors approved a 1-for-10.98 reverse split of the Company’s outstanding common stock.